Cite
Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.
MLA
Dzienis, Marcin, et al. “Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.” Journal of Clinical Oncology, vol. 42, no. 25, Sept. 2024, pp. 2989–99. EBSCOhost, https://doi.org/10.1200/JCO.23.02625.
APA
Dzienis, M., Cundom, J., Fuentes, C. S., Spreafico, A., Nordlinger, M., Pastor, A. V., Alesi, E., Neki, A., Fung, A. S., Figueiredo Lima, I. P., Oppelt, P., da Cunha Junior, G. F., Burtness, B., Franke, F. A., Tseng, J. E., Joshi, A., McCarthy, J., Swaby, R., Sidi, Y., & Gumuscu, B. (2024). Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial. Journal of Clinical Oncology, 42(25), 2989–2999. https://doi.org/10.1200/JCO.23.02625
Chicago
Dzienis, Marcin, Juan Cundom, Christian Sebastian Fuentes, Anna Spreafico, Melanie Nordlinger, Andrea Viviana Pastor, Erin Alesi, et al. 2024. “Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.” Journal of Clinical Oncology 42 (25): 2989–99. doi:10.1200/JCO.23.02625.